Treprostinil曲前列尼尔,81846-19-7

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Treprostinil

CAS No. : 81846-19-7

MCE 国际站：Treprostinil

产品活性：Treprostinil (UT-15) 是高效的DP1和EP2激动剂，其EC₅₀值分别为0.6±0.1和6.2±1.2 nM。

研究领域：GPCR/G Protein

作用靶点：Prostaglandin Receptor

In Vitro: Treprostinil has high affinity for the DP1, EP2 and IP receptors (K_i=4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, FP and TP receptors. Activation of IP, DP1 and EP2 receptors, as with treprostinil, can all result in vasodilatation of human pulmonary arteries.Treprostinil inhibits viability of cultured endothelial colony forming cells. Endothelial colony forming cells proliferation is stimulated by conditioned media from Treprostinil pretreated mesenchymal stem cells.

In Vivo: Inhaled treprostinil sodium, a prostacyclin analog, is the most recent agent to receive FDA approval for the treatment of a fatal orphan disease: pulmonary arterial hypertension (PAH). Treprostinil preserves the sinusoidal endothelial cell lining and reduces platelet deposition early post-transplantation compared to placebo. Hepatic tissue blood flow is significantly compromised in the placebo group, whereas treprostinil maintains blood flow similar to normal levels.Treprostinil treatment significantly increases the vessel-forming ability of endothelial colony forming cells combined with mesenchymal stem cells in Matrigel implanted in nude mice. Silencing VEGF-A gene in mesenchymal stem cells also blocks the pro-angiogenic effect of Treprostinil. Treprostinil is most efficacious in raising intracellular cAMP levels in murine and human hematopoietic stem and progenitor cells. Treatment with Treprostinil significantly reduces the recruitment of cells compared to normoxic mice. Treprostinil also reduces right ventricular systolic pressure and slightly reduces the vascular remodelling but fails to reverse the right ventricular hypertrophy.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Endocrinology Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Angiogenesis-Related Compound Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  Human Metabolite Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Withdrawn Drug Compound Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Prostaglandin E2  |  EIPA  |  Prostaglandin E1  |  Tranilast  |  PF-04418948  |  U-46619  |  Iloprost  |  Prostaglandin D2  |  ONO-AE3-208  |  Dinoprost  |  Palupiprant  |  Latanoprost  |  Selexipag  |  16,16-Dimethyl prostaglandin E2  |  DG-041  |  Grapiprant  |  L-798106  |  GW627368  |  Fevipiprant  |  Asapiprant  |  AH 6809  |  L-161982  |  Laropiprant  |  Bimatoprost  |  CJ-42794  |  MF498  |  Beraprost sodium  |  Ramatroban  |  Travoprost

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds